La vendita allo scoperto per Siegfried Holding dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Siegfried Holding. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Siegfried Holding (OTC:SGFEF) Azioni, Report sulle vendite allo scoperto

Siegfried Holding is a global contract development and manufacturing organization, or CDMO. Siegfried derives its revenue primarily from long-term supply agreements with biotechnology and pharmaceutical customers. Siegfried develops and manufactures active pharmaceutical ingredients, finished dosage forms (tablets, capsules, sterile vials, ampules, cartridges, and ointments), and viral vectors. Siegfried provides these services throughout the entire drug lifecycle, including chemical and analytical development, pilot manufacturing, and commercial-scale manufacturing. Siegfried has a large global footprint with 12 production sites on three continents.

SIEGFRIED HLDGS LTD ORD by Siegfried Holdings Ltd

Siegfried Holding AG

<p><strong>Blue Bird</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBD#NASDAQ">BLBD</a>) just disclosed its Q4 earnings on Monday, November 25, 2024 at 04:00 PM.</p>
<p>Here's a brief overview of the earnings report.</p>
<h3>Earnings</h3>
<p>Blue Bird missed estimated earnings by -16.0%, reporting an EPS of $0.77 versus an estimate of $0.92.</p>
<p>Revenue was up $47.25 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>During the previous quarter, the company beat on EPS by $0.4, leading to a 0.0% increase share price change the next day.</p>
<p>Here's a look at Blue Bird's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.51</td>
<td>0.48</td>
<td>0.37</td>
<td>0.48</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.91</td>
<td>0.89</td>
<td>0.91</td>
<td>0.66</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>328.60M</td>
<td>298.41M</td>
<td>275.13M</td>
<td>290.11M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>333.37M</td>
<td>345.92M</td>
<td>317.66M</td>
<td>302.96M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Blue Bird <a href="https://www.benzinga.com/quote/BLBD/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings

BLBD

Blue Bird Earnings Analysis: Q4 Recap

<p><strong>Enanta Pharma</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) released its Q4 earnings on Monday, November 25, 2024 at 04:01 PM.</p>
<p>Here's what's important from the earnings announcement.</p>
<h3>Earnings</h3>
<p>Enanta Pharma beat estimated earnings by 4.0%, reporting an EPS of $-1.36 versus an estimate of $-1.41.</p>
<p>Revenue was down $4.33 million from the same period last year.</p>
<h3>Overview of Past Earnings</h3>
<p>The company beat on EPS by $0.38 in the last quarter, resulting in a 1.0% increase share price change the following day.</p>
<p>Here's a look at Enanta Pharma's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-1.45</td>
<td>-1.33</td>
<td>-1.19</td>
<td>-2</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-1.07</td>
<td>-1.47</td>
<td>-1.58</td>
<td>-1.33</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>17.18M</td>
<td>16.52M</td>
<td>21.28M</td>
<td>17.50M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>17.97M</td>
<td>17.05M</td>
<td>18.00M</td>
<td>18.93M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Enanta Pharma <a href="https://www.benzinga.com/quote/ENTA/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ENTA

Insights into Enanta Pharma Q4 Earnings

<p>The earnings results for <strong>Central Garden &amp; Pet</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) for Q4 were made public on Monday, November 25, 2024 at 04:02 PM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>Central Garden &amp; Pet beat estimated earnings by 18.0%, reporting an EPS of $-0.18 versus an estimate of $-0.22.</p>
<p>Revenue was down $80.66 million from the same period last year.</p>
<h3>Historical Earnings Summary</h3>
<p>The company beat on EPS by $0.02 in the previous quarter, leading to a 0.0% increase share price change the next day.</p>
<p>Here's a look at Central Garden &amp; Pet's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.20</td>
<td>1.21</td>
<td>0.80</td>
<td>0.76</td>
<td>-0.14</td>
<td>-0.14</td>
<td>0.06</td>
<td>0.06</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.32</td>
<td>1.32</td>
<td>0.99</td>
<td>0.99</td>
<td>0.01</td>
<td>0.01</td>
<td>0.08</td>
<td>0.08</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>1.00B</td>
<td>1.00B</td>
<td>887.42M</td>
<td>883.42M</td>
<td>619.95M</td>
<td>619.95M</td>
<td>735.32M</td>
<td>735.32M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>996.35M</td>
<td>996.35M</td>
<td>900.09M</td>
<td>900.09M</td>
<td>634.53M</td>
<td>634.53M</td>
<td>750.15M</td>
<td>750.15M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Central Garden &amp; Pet <a href="https://www.benzinga.com/quote/CENTA/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CENTA

Central Garden & Pet Q4 Earnings Assessment

<p><strong>New Jersey Resources</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NJR#NYSE">NJR</a>) just disclosed its Q4 earnings on Monday, November 25, 2024 at 04:30 PM.</p>
<p>Here's a brief overview of the earnings report.</p>
<h3>Earnings</h3>
<p>New Jersey Resources beat estimated earnings by 1.0%, reporting an EPS of $0.89 versus an estimate of $0.88.</p>
<p>Revenue was up $64.45 million from the same period last year.</p>
<h3>Performance in Previous Earnings</h3>
<p>During the previous quarter, the company missed on EPS by $0.08, leading to a 2.0% increase share price change the next day.</p>
<p>Here's a look at New Jersey Resources's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.01</td>
<td>1.32</td>
<td>0.75</td>
<td>0.32</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.09</td>
<td>1.41</td>
<td>0.74</td>
<td>0.30</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>283.00M</td>
<td>670.00M</td>
<td>662.00M</td>
<td>760.00M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>275.64M</td>
<td>657.91M</td>
<td>467.21M</td>
<td>331.32M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for New Jersey Resources <a href="https://www.benzinga.com/quote/NJR/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Recap: New Jersey Resources Q4 Earnings

<p><strong>Chegg, Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHGG#NYSE">CHGG</a>) shares traded higher on Monday after the company announced a repurchase agreement for its 0% convertible senior notes due 2026. Here&#8217;s<a href="https://www.benzinga.com/quote/CHGG/news"> what you need to know.</a></p>
<p><strong>What To Know</strong>: Chegg has entered into private agreements with certain noteholders to repurchase approximately $116.6 million of its outstanding 0% convertible senior notes due 2026 for a cash price of $96.2 million. The repurchase transactions were entered into as part of Chegg's previously announced securities repurchase program.</p>
<p>The note repurchases are expected to close on Dec. 3. Following closing, $127.9 million aggregate principal amount of the notes will remain outstanding, while $207.5 million will remain available for repurchases under the program.</p>
<p>The move reduces the company's outstanding debt, which appears to have contributed to Monday&#8217;s positive market reaction. Chegg provides learning support services through its platform, offering AI-powered academic assistance and access to subject matter experts. </p>
<p>Chegg reported better-than-expected financial results for the third quarter earlier this month. Multiple analysts lowered price targets following the report, ranging from $1.50 to $3 per share. </p>
<p><strong>CHGG Price Action:</strong> Chegg shares closed Monday up 12.2% at $2.26, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a></p>
<p><figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="545" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25153805/CHGG-1024x545.png" alt="" class="wp-image-664186" style="width:459px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25153805/CHGG-1024x545.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25153805/CHGG-300x160.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25153805/CHGG-768x409.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25153805/CHGG.png 1437w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/24/11/42173927/how-rich-are-you-find-out-whether-you-rank-as-upper-middle-or-lower-class-based-on-income-and-other-factors">How Rich Are You? Find Out Whether You Rank As Upper, Middle Or Lower Class Based On Income And Other Factors</a></strong></li>
</ul>
<p><em>Photo via Shutterstock.</em></p>


News

Movers

CHGG

Chegg Shares Rallied On Monday: What Happened?

<p><strong>Tesla Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares closed lower on Monday. Reports indicate Tesla vehicles would not be eligible for rebates under a new California <a href="https://www.benzinga.com/news/24/07/39846836/california-ev-subsidies-made-tesla-what-it-is-but-elon-musk-is-ready-to-cut-them-off-remove-subsidie">consumer rebates proposal</a>.</p>
<p><strong>What Happened:</strong> According to a Bloomberg <a href="https://www.bloomberg.com/news/articles/2024-11-25/california-pledges-ev-buyer-rebate-if-trump-kills-7-500-credit?sref=TBDibEcD&amp;embedded-checkout=true">report</a>, California Governor <strong>Gavin Newsom</strong> outlined new plans on Monday to offer incentives for EV buyers in California if President-elect <strong>Donald Trump</strong> gets rid of the current federal $7,500 tax break for EV buyers when he returns to the White House early next year.</p>
<p>Newsom&#8217;s team reportedly told Bloomberg that the new proposal includes &#8220;market-share limitations&#8221; that would exclude Tesla&#8217;s EV models from tax credit eligibility.</p>
<p>"It's about creating the market conditions for more of these car makers to take route,"&nbsp;the governor&#8217;s office reportedly said.</p>
<p>Tesla CEO <strong>Elon Musk</strong> and Newsom have a &#8220;tense&#8221; relationship dating back to before Musk decided to move Tesla&#8217;s headquarters out of California. Musk pushed back against state orders to close the company&#8217;s factory during the COVID-19 pandemic, calling them &#8220;fascist.&#8221; Newsom reportedly said Tesla owed some of its success to California.</p>
<p>The news follows reports from earlier this month indicating that Trump's team plans to kill the $7,500 EV tax credit on vehicle purchases as part of a broader tax-reform plan.</p>
<p><strong>See Also: <a href="https://www.benzinga.com/government/regulations/24/11/42160725/tesla-faces-environmental-violations-as-elon-musks-doge-prepares-for-garbage-collection-of-rules-that-dont-make-sense-report">Tesla Faces Environmental Violations As Elon Musk&#8217;s &#8216;DOGE&#8217; Prepares For &#8216;Garbage Collection Of Rules That Don&#8217;t Make Sense:&#8217; Report</a></strong></p>
<p>Musk reportedly told Trump's team that he supports <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41988194/trump-plans-to-erase-ev-tax-credit-analyst-says-its-net-bullish-calls-sell-off-wrong-knee-jerk-reaction">putting an end to the EV tax credit</a>. The Tesla CEO said earlier this year that removing the EV tax credit could have a slight impact on Tesla sales, but would be far worse for Tesla&#8217;s U.S.-based competitors. Analysts seem to agree.</p>
<p>Wedbush analyst&nbsp;<strong>Dan Ives</strong>&nbsp;said in a note following the news that the cuts are actually&nbsp;<a href="https://www.benzinga.com/trading-ideas/24/11/41985486/if-tesla-stock-hits-all-time-highs-in-2025-will-it-be-driven-by-trump-musk-relationship-benzinga-readers-say-this" target="_blank" rel="noreferrer noopener">net positive for Tesla</a>. The Wedbush analyst acknowledged that getting rid of the tax credit could weigh on demand, but he believes it will actually propel Tesla further ahead of competitors.&nbsp;</p>
<p>"We expect Musk to have a big seat at the table as these EV discussions happen within the Trump transition team. We believe any sell-off in Tesla from these reports is the wrong knee-jerk reaction and we would be buyers," Ives said in a recent Tesla note.</p>
<p>UBS analyst Joseph Spak maintained Tesla with a <a href="https://www.benzinga.com/analyst-stock-ratings">Sell rating</a> on Monday and raised the price target from&nbsp;$197&nbsp;to&nbsp;$226.</p>
<p><strong>TSLA Price Action:</strong> <a href="http://benzinga.com/quote/tsla">Tesla shares</a> are up approximately 31% over the past month. The EV stock was down 3.96% at $338.59 at the time of publication Monday, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.</p>
<p><em>Photo: courtesy of Tesla.</em></p>


TSLA

What's Going On With Tesla Stock Today?

Guidance

FLNC

Fluence Energy Expects FY25 Revenue Of Approximately $3.6B - $4.4B With Midpoint Of $4.0B (Est $3.948B)

<p><strong>SMARTCELLs with integrated Veea Edge Platform offer a practical solution for collection and processing of massive amounts of data for highly unique AI-driven edge applications</strong></p>
<p>Visit our Booth #510 at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ffall.smartcitiesconnect.org%2F&amp;esheet=54158095&amp;newsitemid=20241125091566&amp;lan=en-US&amp;anchor=Smart+Cities+Connect+Conference&amp;index=1&amp;md5=4b23dc81dbe3ae7ce6d4ca86d8452596">Smart Cities Connect Conference</a> in Austin, TX, December 3-5, 2024</p>
<p>MARQUEE Wireless Inc., a company specializing in integrationand deployment ofcellular, IoT andedge computing technologiesfor cellular networks and Smart Cities, and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.veea.com%2F&amp;esheet=54158095&amp;newsitemid=20241125091566&amp;lan=en-US&amp;anchor=Veea+Inc.&amp;index=2&amp;md5=76fd2ac704fd03a9954b41352a07faf3">Veea Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEEA#NASDAQ">VEEA</a>), a pioneer in hyperconverged Multiaccess Edge Computing (MEC) with AI-driven cybersecurity and edge solutions, announced a partnership for a visionary initiative to roll out a transformative solution based on MARQUEE's patented SMARTCELL&#x2122; platform supported by Veea's Decentralized Physical Infrastructure Network (DePIN) to accelerate the introduction of MEC solutions with Edge AI as an extension of cellular network infrastructure.</p>


VEEA

VEEA Announces A Partnership For A Visionary Initiative To Roll Out A Transformative Solution Based On  MARQUEE's Patented SMARTCELL Platform Supported By Veea's Decentralized Physical Infrastructure Network To Accelerate The Introduction Of MEC Solutions With Edge AI As An Extension Of Cellular Network Infrastructure

<p>New Jersey Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NJR#NYSE">NJR</a>) reported quarterly earnings of $0.89 per share which beat the analyst consensus estimate of $0.88 by 1.14 percent.  The company reported quarterly sales of $395.780 million which missed the analyst consensus estimate of $407.000 million by 2.76 percent.  This is a 19.45 percent increase over sales of $331.325 million the same period last year.</p>


Earnings Beats

Earnings Misses

New Jersey Resources Q4 2024 Adj. EPS $0.89 Beats $0.88 Estimate, Sales $395.780M Miss $407.000M Estimate

Dana Announces Plan To Sell Off-Highway Business; Co. Also Initiates Cost Reduction Plan, Expecting To Deliver Annualized Savings Of ~$200M By 2026, Says Plans To Reduce Capital Spending To Reflect The Revised Market Demand For Electric Vehicles

<ul>
<li><i>Ashley Buchanan Appointed Chief Executive Officer and Board Member, Starting January 15</i></li>
<li><i>Tom Kingsbury Plans to Step Down as CEO on January 15, Retaining an Executive Advisory Role and Board Seat Through His Retirement in May 2025</i></li>
</ul>
<p>Kohl's Corporation ("Kohl's" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) today announced that Chief Executive Officer Tom Kingsbury plans to step down as CEO, effective January 15, 2025. He will stay on in an advisory role to the new CEO and retain his position on Kohl's Board of Directors (the "Board") through his retirement in May 2025, after which the size of the board will be reduced by one.</p>
<p>The Board has appointed retail veteran Ashley Buchanan as CEO, effective January 15. Buchanan has been CEO of Michaels Companies since 2020 and, prior to that, has held a variety of senior executive roles at Walmart and Sam's Club during his 13 years at the company.</p>


Management

Kohl's Announces CEO Transition Process; Ashley Buchanan Appointed CEO And Board Member, Starting January 15; Tom Kingsbury Plans To Step Down As CEO On January 15, Retaining An Executive Advisory Role And Board Seat Through His Retirement In May 2025

Dana Appoints Current Director R. Bruce McDonald As Chairman And CEO

<p>Universal Health Realty Income Trust (NYSE:&nbsp;UHT) announced today that its Board of Trustees voted to increase the quarterly dividend by $.005 and pay a dividend of $.735 per share on December 31, 2024 to shareholders of record as of December 16, 2024.</p>


Dividends

Universal Health Realty Income Trust Announces Dividend Increase From $0.73 To $0.735 Per Share

<p><strong>Blue Bird</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBD#NASDAQ">BLBD</a>) reported its Q4 earnings results on Monday, November 25, 2024 at 04:00 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Blue Bird missed estimated earnings by -16.0%, reporting an EPS of $0.77 versus an estimate of $0.92.</p>
<p>Revenue was up $47.25 million from the same period last year.</p>
<h3>Analysis of Past Earnings</h3>
<p>In the previous quarter, the company beat on EPS by $0.4, resulting in a 0.0% increase change in the share price the following day.</p>
<p>Here's a look at Blue Bird's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.51</td>
<td>0.48</td>
<td>0.37</td>
<td>0.48</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.91</td>
<td>0.89</td>
<td>0.91</td>
<td>0.66</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>328.60M</td>
<td>298.41M</td>
<td>275.13M</td>
<td>290.11M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>333.37M</td>
<td>345.92M</td>
<td>317.66M</td>
<td>302.96M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Blue Bird <a href="https://www.benzinga.com/quote/BLBD/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Blue Bird Earnings Review: Q4 Summary

<p><strong>Woodward</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) reported its Q4 earnings results on Monday, November 25, 2024 at 04:00 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Woodward beat estimated earnings by 13.0%, reporting an EPS of $1.41 versus an estimate of $1.25.</p>
<p>Revenue was up $77.42 million from the same period last year.</p>
<h3>Analysis of Past Earnings</h3>
<p>The company beat on EPS by $0.12 in the last quarter, resulting in a 17.0% drop share price change the following day.</p>
<p>Here's a look at Woodward's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.51</td>
<td>1.32</td>
<td>1.10</td>
<td>1.31</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.63</td>
<td>1.62</td>
<td>1.45</td>
<td>0.84</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>853.82M</td>
<td>807.00M</td>
<td>748.29M</td>
<td>765.35M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>847.69M</td>
<td>835.34M</td>
<td>786.73M</td>
<td>777.07M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Woodward management provided guidance for FY 2025, expecting earnings between $5.75 and $6.25 per share.</p>
<p>To track all earnings releases for Woodward <a href="https://www.benzinga.com/quote/WWD/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Woodward Earnings Report: Q4 Overview

<p><strong>Enanta Pharma</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) released its Q4 earnings on Monday, November 25, 2024 at 04:01 PM.</p>
<p>Here's what's important from the earnings announcement.</p>
<h3>Earnings</h3>
<p>Enanta Pharma beat estimated earnings by 4.0%, reporting an EPS of $-1.36 versus an estimate of $-1.41.</p>
<p>Revenue was down $4.33 million from the same period last year.</p>
<h3>Previous Earnings Records</h3>
<p>The company beat on EPS by $0.38 in the previous quarter, leading to a 1.0% increase share price change the next day.</p>
<p>Here's a look at Enanta Pharma's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-1.45</td>
<td>-1.33</td>
<td>-1.19</td>
<td>-2</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-1.07</td>
<td>-1.47</td>
<td>-1.58</td>
<td>-1.33</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>17.18M</td>
<td>16.52M</td>
<td>21.28M</td>
<td>17.50M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>17.97M</td>
<td>17.05M</td>
<td>18.00M</td>
<td>18.93M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Enanta Pharma <a href="https://www.benzinga.com/quote/ENTA/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Enanta Pharma: Q4 Earnings Insights

<p><strong>Central Garden &amp; Pet</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENT#NASDAQ">CENT</a>) announced its Q4 earnings on Monday, November 25, 2024 at 04:02 PM.</p>
<p>Here's a breakdown of the earnings report.</p>
<h3>Earnings</h3>
<p>Central Garden &amp; Pet beat estimated earnings by 10.0%, reporting an EPS of $-0.18 versus an estimate of $-0.2.</p>
<p>Revenue was down $80.66 million from the same period last year.</p>
<h3>Overview of Past Earnings</h3>
<p>During the previous quarter, the company beat on EPS by $0.11, leading to a 6.0% increase share price change the next day.</p>
<p>Here's a look at Central Garden &amp; Pet's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.21</td>
<td>0.80</td>
<td>-0.14</td>
<td>0.06</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.32</td>
<td>0.99</td>
<td>0.01</td>
<td>0.08</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>1.00B</td>
<td>887.42M</td>
<td>619.95M</td>
<td>735.32M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>996.35M</td>
<td>900.09M</td>
<td>634.53M</td>
<td>750.15M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Central Garden &amp; Pet <a href="https://www.benzinga.com/quote/CENT/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CENT

Insights into Central Garden & Pet Q4 Earnings

<p><strong>Pennant Park Investment</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNNT#NYSE">PNNT</a>) reported its Q4 earnings results on Monday, November 25, 2024 at 04:05 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Pennant Park Investment missed estimated earnings by 0.0%, reporting an EPS of $0.22 versus an estimate of $0.22.</p>
<p>Revenue was up $2.46 million from the same period last year.</p>
<h3>Analysis of Past Earnings</h3>
<p>During the previous quarter, the company beat on EPS by $0.01, leading to a 1.0% increase share price change the next day.</p>
<p>Here's a look at Pennant Park Investment's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.23</td>
<td>0.24</td>
<td>0.23</td>
<td>0.22</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.24</td>
<td>0.22</td>
<td>0.24</td>
<td>0.24</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>36.66M</td>
<td>36.34M</td>
<td>32.74M</td>
<td>34.83M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>37.00M</td>
<td>35.98M</td>
<td>34.34M</td>
<td>34.04M</td>
</tr>
</tbody>
</table>
</p>
<p><strong> Listen to the earnings announcement yourself by <a href="">clicking here</a>. </strong></p>
<p>To track all earnings releases for Pennant Park Investment <a href="https://www.benzinga.com/quote/PNNT/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


PNNT

Recap: Pennant Park Investment Q4 Earnings

<p>The earnings results for <strong>PennantPark Floating Rate</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFLT#NYSE">PFLT</a>) for Q4 were made public on Monday, November 25, 2024 at 04:05 PM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>PennantPark Floating Rate missed estimated earnings by 0.0%, reporting an EPS of $0.32 versus an estimate of $0.32.</p>
<p>Revenue was up $19.79 million from the same period last year.</p>
<h3>Historical Earnings Summary</h3>
<p>During the previous quarter, the company missed on EPS by $0.01, leading to a 0.0% increase share price change the next day.</p>
<p>Here's a look at PennantPark Floating Rate's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.32</td>
<td>0.32</td>
<td>0.31</td>
<td>0.31</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.31</td>
<td>0.31</td>
<td>0.33</td>
<td>0.32</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>45.52M</td>
<td>39.45M</td>
<td>35.01M</td>
<td>34.59M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>48.51M</td>
<td>44.35M</td>
<td>37.97M</td>
<td>35.73M</td>
</tr>
</tbody>
</table>
</p>
<p><strong> Listen to the earnings announcement yourself by <a href="">clicking here</a>. </strong></p>
<p>To track all earnings releases for PennantPark Floating Rate <a href="https://www.benzinga.com/quote/PFLT/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


PFLT

PennantPark Floating Rate Earnings Review: Q4 Summary

<p>The earnings results for <strong>StealthGas</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GASS#NASDAQ">GASS</a>) for Q3 were made public on Monday, November 25, 2024 at 09:10 AM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>StealthGas beat estimated earnings by 15.0%, reporting an EPS of $0.38 versus an estimate of $0.33.</p>
<p>Revenue was up $5.79 million from the same period last year.</p>
<h3>Overview of Past Earnings</h3>
<p>The company beat on EPS by $0.22 in the last quarter, resulting in a 2.0% drop share price change the following day.</p>
<p>Here's a look at StealthGas's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.53</td>
<td>0.24</td>
<td>0.30</td>
<td>0.15</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.75</td>
<td>0.53</td>
<td>0.29</td>
<td>0.16</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>39.20M</td>
<td>34.30M</td>
<td>33.90M</td>
<td>27.50M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>41.79M</td>
<td>41.56M</td>
<td>34.14M</td>
<td>34.65M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for StealthGas <a href="https://www.benzinga.com/quote/GASS/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


GASS

StealthGas Q3 Earnings Assessment

In a report released today, Edward Hall CFA from Stifel Nicolaus maintained a Buy rating on Siegfried Holding AG (SGFEF – Research Report), with a ...

Siegfried Holding AG: Strong Market Position and Financial Health Prompt 'Buy' Rating

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Siegfried Holding AG (SGFEF – Research Report) and Sanofi (SNYNF ...

Analysts Offer Insights on Healthcare Companies: Siegfried Holding AG (OtherSGFEF) and Sanofi (OtherSNYNF)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Diaceutics (DIUXF – Research Report) and Siegfried H...

Analysts Are Bullish on These Healthcare Stocks: Diaceutics (DIUXF), Siegfried Holding AG (SGFEF)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Siegfried Holding AG (SGFEF – Research Report) and T...

Analysts Offer Insights on Healthcare Companies: Siegfried Holding AG (OtherSGFEF) and Travere Therapeutics (TVTX)

Analyst Edward Hall CFA from Stifel Nicolaus maintained a Buy rating on Siegfried Holding AG (SGFEF – Research Report) and keeping the price target...

Siegfried Holding AG: Strong Financial Performance and Positive Outlook Reinforce Buy Rating

In a report released yesterday, Charles Weston from RBC Capital maintained a Hold rating on Siegfried Holding AG (SGFEF – Research Report), with a ...

RBC Capital Keeps Their Hold Rating on Siegfried Holding AG (SGFEF)

In a report released today, Barbora Blaha from UBS maintained a Buy rating on Siegfried Holding AG (SGFEF – Research Report), with a price target o...

Siegfried Holding AG (SGFEF) Gets a Buy from UBS

TimesSquare International Small Cap Strategy Commentary -- 3Q24

Analysts fell to the sidelines weighing in on Sanofi (SNYNF – Research Report), Siegfried Holding AG (SGFEF – Research Report) and Terveystalo Oy (...

Analysts Are Neutral on Top Healthcare Stocks: Sanofi (SNYNF), Siegfried Holding AG (SGFEF)

In a report released today, Edward Hall CFA from Stifel Nicolaus reiterated a Hold rating on Siegfried Holding AG (SGFEF – Research Report), with a...

Comments

Siegfried Holding

Vendite allo scoperto

Siegfried Holding (OTC:SGFEF) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO